The glycerol-3-phosphate acyltransferase mitochondrial (GPAM) antibody is a tool used to study GPAM, a key enzyme in lipid biosynthesis. GPAM catalyzes the initial step of glycerophospholipid and triglyceride synthesis by acylating glycerol-3-phosphate to form lysophosphatidic acid. This mitochondrial enzyme plays a central role in regulating lipid metabolism, energy homeostasis, and cellular membrane formation. Dysregulation of GPAM activity is linked to metabolic disorders such as obesity, insulin resistance, non-alcoholic fatty liver disease (NAFLD), and cardiovascular diseases. Researchers employ GPAM antibodies in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect GPAM expression levels, subcellular localization, and tissue distribution. These studies aim to elucidate GPAM's role in lipid-related pathologies and its potential as a therapeutic target. The antibody's specificity enables investigations into how GPAM interacts with metabolic pathways, responds to nutritional cues, or contributes to ectopic lipid accumulation. Recent work also explores GPAM inhibition as a strategy to reduce lipid storage and improve metabolic health, highlighting the antibody's relevance in both basic research and drug development.